Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing
Drug Is Second Asset Under Companies' Partnership
Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.
You may also be interested in...
The US- and China-based biotech is expanding three oncology-centered clinical studies of two TGF-1/COX-2-targeted siRNA drug candidates from the US into China.
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.